↓ Skip to main content

Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA

Overview of attention for article published in Cancer Discovery, October 2023
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
11 news outlets
twitter
52 X users

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
22 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
Published in
Cancer Discovery, October 2023
DOI 10.1158/2159-8290.cd-23-0456
Pubmed ID
Authors

Derek Wong, Ping Luo, Leslie E. Oldfield, Haifan Gong, Ledia Brunga, Ron Rabinowicz, Vallijah Subasri, Clarissa Chan, Tiana Downs, Kirsten M. Farncombe, Beatrice Luu, Maia Norman, Julia A. Sobotka, Precious Uju, Jenna Eagles, Stephanie Pedersen, Johanna Wellum, Arnavaz Danesh, Stephenie D. Prokopec, Eric Y. Stutheit-Zhao, Nadia Znassi, Lawrence E. Heisler, Richard Jovelin, Bernard Lam, Beatriz E. Lujan Toro, Kayla Marsh, Yogi Sundaravadanam, Dax Torti, Carina Man, Anna Goldenberg, Wei Xu, Patrick Veit-Haibach, Andrea S. Doria, David Malkin, Raymond H. Kim, Trevor J. Pugh

Abstract

People with Li-Fraumeni syndrome harbor a germline pathogenic variant in the TP53 tumor suppressor gene; face a near 100% lifetime risk of cancer; and routinely undergo intensive surveillance protocols. Liquid biopsy has become an attractive tool for a range of clinical applications, including early cancer detection. Here, we provide a proof-of-principle for a multi-modal liquid biopsy assay that integrates a targeted gene panel, shallow whole genome, and cell-free methylated DNA immunoprecipitation sequencing for the early detection of cancer in a longitudinal cohort of 89 Li-Fraumeni syndrome patients. Multi-modal analysis increased our detection rate in patients with an active cancer diagnosis over uni-modal analysis; and was able to detect cancer-associated signal in carriers prior to diagnosis with conventional screening (PPV = 67.6%, NPV = 96.5%). While adoption of liquid biopsy into current surveillance will require further clinical validation, this study provides a framework for individuals with Li-Fraumeni syndrome.

X Demographics

X Demographics

The data shown below were collected from the profiles of 52 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 22 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 6 27%
Researcher 4 18%
Other 2 9%
Student > Master 2 9%
Student > Postgraduate 1 5%
Other 4 18%
Unknown 3 14%
Readers by discipline Count As %
Unspecified 7 32%
Biochemistry, Genetics and Molecular Biology 5 23%
Medicine and Dentistry 3 14%
Agricultural and Biological Sciences 1 5%
Chemistry 1 5%
Other 1 5%
Unknown 4 18%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 108. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2024.
All research outputs
#387,681
of 25,383,225 outputs
Outputs from Cancer Discovery
#188
of 4,053 outputs
Outputs of similar age
#6,834
of 350,034 outputs
Outputs of similar age from Cancer Discovery
#10
of 101 outputs
Altmetric has tracked 25,383,225 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,053 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.5. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,034 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 101 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.